Real Estate Pro, mom of three and Mimi x2 . Multiple Myeloma Thriver. Lover of live music, travel, a good read and bold food. Motto: Live Now, never delay joy!
ICYMI: In newly diagnosed multiple myeloma (NDMM), the addition of daratumumab (D) to the KRd regimen significantly improved minimal residual disease (MRD) negativity.
In the ADVANCE clinical trial (NCT04268498), 306 patients received either DKRd or KRd for 8 cycles. Results show a 2.5-fold increase in MRD negativity with DKRd (59% vs 36%). Despite some adverse events, no new safety concerns emerged. These promising results suggest DKRd should become the new standard for NDMM patients receiving KRd-based therapy.
@DrOlaLandgren presented these findings at the 2025 @ASCO Annual Meeting. Learn more: https://t.co/2CZqwhzsEV #ASCO25 #MMsm
If you missed the first article in my masks in healthcare series, you can read it below.
It’s a Plea to Healthcare Workers from Vulnerable Patients.
Please respect the trust we’re placing in you and wear a mask to keep us safe:
https://t.co/J3194CEgDk
MajesTEC-5 -
Arm A/A1: Teclistamab + Dara + Len --> ASCT --> Tec-Dara
Arm B: Tec-Dara-V-R
Toxicity: 60-70% CRS, G1-2; 35% G3+ infections (everybody getting some infections)
Efficacy (amazing!)
Everybody is MRD negative after just 3 cycles!
Stem cell yields not affected
To me, begs the questions:
- Is bortezomib really needed?
- Is ASCT really needed?
- Is post-ASCT maintenance critical?
#ASH24 #mmMRD